Epithalon side effects: an empty column is not a clean record
Start with what would have to be true for none reported to mean what readers assume.
It would need a system that receives reports. A population using the compound in a way that could be tracked. A definition of what counts as an adverse event. Someone comparing the rate of events against what would be expected anyway in people of that age. And an authority able to demand answers from a manufacturer when a pattern appears.
This compound holds no marketing authorisation in any country. There is no approved label, so no leaflet lists harms. There is no registered interventional trial, so no study protocol committed anyone to collecting them. There is no national reporting scheme covering it, because such schemes attach to licensed products. And there is no manufacturer with legal responsibility to answer for a batch.
Every one of the conditions above is missing. What remains is silence, and silence is being sold as safety.
Nobody is collecting, so nothing can be reported
This distinction is easy to state and surprisingly hard to hold onto, so it is worth an example from a familiar setting.
When a licensed medicine goes into wide use, uncommon harms surface gradually. A prescriber notices something odd. A pharmacist files a report. Reports accumulate from many places, get compared against background rates, and eventually a signal separates from noise. It is slow, it is imperfect, and it is the only mechanism that catches events too rare for any trial to detect.
None of that machinery exists here. If a person using this compound develops a problem months later, there is no channel that would receive the information, no database it would join and nobody who would ever count it. Their experience would be visible to their own doctor, if they mentioned it, and to nobody else.
So the honest phrasing is not that the compound has no side effects. It is that no system capable of finding them has ever been pointed at it.
Safety reported by the people who developed it
The published literature on this compound is concentrated in the research programme of Khavinson and colleagues in St Petersburg, and safety impressions come largely from the same source as the efficacy claims.
This is not a charge of bad faith. It is a structural point about who is reporting on what. Tolerability described by the group that developed a compound, in the absence of any independent collection, is the weakest version of a safety claim available. Independent replication does for safety exactly what it does for efficacy: it brings in observers with different techniques, different populations and no stake in the answer.
The claims themselves also constrain what the existing work could have found. Studies in cultured cells cannot report human adverse effects. Studies in rodents report what happened to rodents. Neither is designed to catch something uncommon or slow, which is the category of harm that matters most for a compound taken by healthy people over long periods.
Where each kind of harm would have to be detected
The right hand column is the whole article in one column. Only the rows a single person can observe for themselves are covered, and those are the least important rows for a compound whose promise is measured in decades.
| Type of harm | Where it would show up | Who would have to be looking | Available anywhere |
|---|---|---|---|
| Immediate reaction | Within hours of use | The user, and a clinician if involved | Partly, and only to that person |
| Contamination or residue from manufacture | Batch testing | An accredited laboratory | Rarely, and usually identity only |
| Infection from non sterile material | Days after use | The user and their doctor | Yes, after the fact |
| Uncommon reaction | Across thousands of users | A national reporting scheme | No, for an unlicensed compound |
| Slow harm appearing after years | Long term follow up | A cohort study or registry | No |
| Interaction with existing medication | Reference sources | A prescriber consulting them | No sources exist for this compound |
The theoretical concern the marketing never raises
If the central mechanism claim is taken seriously, it carries a question with it, and consistency requires raising both together.
The compound is sold on reports, from the originating programme and largely in cultured cells, that it increases telomerase activity. Telomerase extends the repeated sequences at the ends of chromosomes and is associated with a cell's capacity to keep dividing. That capacity is desirable in a tissue that needs renewal. It is also a feature of cells that have escaped normal limits on division, which is why the relationship between telomerase activity and cancer risk is an open question in the wider research field rather than a settled one.
Nobody has the evidence to close that question in either direction for this compound. That is not a claim that it causes harm, and it should not be read as one. It is an observation that a page cannot advertise a mechanism as its main selling point while treating the known open question about that same mechanism as irrelevant.
A provider who raises this unprompted is being straight with you. One who has never considered it has not read far enough into the topic they are charging for.
Healthy people, over years, is the exposure nobody studied
Almost everyone buying this compound intends the same pattern of use: a person without a diagnosed illness, taking it repeatedly over a long period, for prevention rather than treatment.
That is the hardest exposure to justify from evidence, for a simple reason. The person has nothing wrong with them, so there is no benefit large enough to be obvious and no condition whose resolution would signal that it worked. Any harm has to be weighed against a benefit that is theoretical. And the timescale over which both would appear is longer than anyone has observed.
Prevention in healthy people is the setting where regulated medicine demands the most evidence, precisely because the tolerance for harm is lowest when nobody is ill. It is also the setting in which this compound has the least. That inversion is the main thing to take away.
What one practice can notice and what escapes it
A clinic is worth something here and it is worth being specific about the boundary.
A good provider will take a history, ask what else you take, notice if something changes, respond if you report a problem and be reachable afterwards. Those are genuine services and they reduce genuine risks, particularly the interaction risks that come from the person rather than the vial.
What no single practice can do is detect a pattern. An uncommon event is invisible to any one observer, because one observer never sees enough cases. Detecting it requires pooling across many practices, comparing against expected rates and having the authority to investigate. That is a national function and unlicensed compounds sit outside it.
So when a clinic tells you they have never seen a problem, believe them and understand what it means. It means their client list is smaller than the number of exposures required to see one.